Transcription factor involved in the induction of oxygen regulated genes. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation seems to require recruitment of transcriptional coactivators such as CREBPB and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD. Efficient DNA binding requires dimerization with another bHLH protein. Heterodimerizes with ARNT. Interacts with CREBBP. Interacts with EGLN1. Interacts with VHL. Expressed in most tissues, with highest levels in placenta, lung and heart. Selectively expressed in endothelial cells. Note: This description may include information from UniProtKB.
Molecular Function: histone acetyltransferase binding; protein binding; signal transducer activity; DNA binding; sequence-specific DNA binding; protein heterodimerization activity; transcription factor binding
Biological Process: transcription from RNA polymerase II promoter; myoblast cell fate commitment; mitochondrion organization and biogenesis; embryonic placenta development; somatic stem cell maintenance; regulation of heart rate; cell maturation; signal transduction; norepinephrine metabolic process; iron ion homeostasis; visual perception; response to hypoxia; erythrocyte differentiation; blood vessel remodeling; positive regulation of transcription from RNA polymerase II promoter; angiogenesis; regulation of transcription from RNA polymerase II promoter in response to oxidative stress; surfactant homeostasis; lung development
Alt. Names/Synonyms: Basic-helix-loop-helix-PAS protein MOP2; BHLHE73; Class E basic helix-loop-helix protein 73; ECYT4; endothelial PAS domain protein 1; Endothelial PAS domain-containing protein 1; EPAS-1; EPAS1; HIF-1-alpha-like factor; HIF-1alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; hypoxia-inducible factor 2 alpha; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; MOP2; PAS domain-containing protein 2; PASD2
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.